General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
Hosted on MSN29d
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?In 2022, Pfizer made a $5.4 billion investment in Global Blood Therapeutics and its sickle cell disease therapy Oxbryta. This September, a safety scare caused the company to pull Oxbryta from the ...
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Pfizer has confirmed that it made an offer of £46.61 ($76.62) per AstraZeneca share in January – a premium of around 30% to AstraZeneca's closing share on 3 January 2014, and valuing the firm ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback